Released Nov 8, 2022, after the close
10-Q filed Nov 9, 2022, 40 days after period end · 0001636422-22-000051
Q3 2022 · 10-Q
Revenue$68.35M$68.35M +10.7% vs Q3 2021−3.2% vs Q2 2022
Net Income-$45.74M-$45.74M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.84-$0.84 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$45,721,000N/M
Operating Cash Flowderived-$12,031,000N/M
Free Cash Flowderived-$13,225,000N/M
Margins · derived
Operating margin-66.9%+1.5 pt vs Q3 2021
Net margin-66.9%−2.1 pt vs Q3 2021
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $68.35M | $61.74M | $47.19M | $39.42M |
| Net Income | -$45.74M | -$40.01M | -$27.33M | -$21.42M |
| EPS Diluted | -$0.84 | -$0.82 | -$0.68 | -$1.40 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Health Catalyst, Inc. · CIK 1636422 · Engraved from SEC EDGAR